The following trends in 2020 were identified in Europe:
- Financing volumes in the European Life Sciences sector have reached a new record high of approximately EUR 8.6bn in 2020 (an increase of +38% compared to 2019) while the number of deals have slightly decreased
- UK continued to record the most transactions and highest volumes throughout the last 5 years
- In 2020, the biotechnology sector leads with EUR 5.3bn, by far, in aggregated deal volumes, however, the medical technology sector has recorded the highest number of deals (465)
- Oncology was again the most targeted indication within the biotechnology sector in 2020 (96 deals), followed by Infectious Diseases with 35 deals
- With a financing volume of EUR 560m, CureVac is leading the top 10 European Life Sciences Deals in 2020
- Cross-border investors tend to play a more important role, especially in later stage rounds, with the US being the most important cross-border investor in Europe
Capital Markets Research
We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:
Venture Capital
Licensing
Healthcare & Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the European Life Sciences sector
Healthcare & Life Sciences Venture Capital Monitor – USAMonthly Venture capital activities in the US Life Sciences sector
Life Sciences Venture Capital ReportRecent Venture capital trends in the European Life Sciences sector
Other Research
Life Sciences IPO ReportRecent IPO trends in the Life Sciences sector
Biotech Public Equity MonitorRecent valuations of listed European Life Sciences companies
MedTech & Diagnostics Public Equity MonitorRecent valuations of listed MedTech companies
Life Sciences SPAC MonitorPerformance overview of merged Life Sciences SPACs
NEWS
FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 02/2024 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 02/2024”. The Monitor is a monthly published overview of venture capital trends in
FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 01/2024 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 01/2024”. The Monitor is a monthly published overview of venture capital trends in
FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 01/2024 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 01/2024”. The Monitor is a monthly published overview of venture capital trends in the
FCF Biotech Venture Capital Monitor – USA 12/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 12/2023”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 12/2023 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 12/2023”. The Monitor is a monthly published overview of venture capital trends in the European
